We are live on ! Find out more
AEON icon

AEON Biopharma

22 hedge funds and large institutions have $1.67M invested in AEON Biopharma in 2025 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,462% more capital inflows, than outflows

Capital inflows: $1.03M | Capital outflows: $22.7K

700% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 1

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

8.92% more ownership

Funds ownership: 11.72% → 20.64% (+8.9%)

5% more funds holding

Funds holding: 21 → 22 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
22
Holders Change
+1
Holders Change %
+4.76%
% of All Funds
0.26%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
4
Increased
8
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

AEON Hedge Fund Activity: Q4 2025 in Review

22 of the 8,309 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q4 2025, worth a combined $1.67M — up 51% from $1.1M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new AEON positions and 3 closed out — a net gain of 1 holder — while 8 added to existing stakes and 1 trimmed.

The largest buyer was Dauntless Investment Group, adding an estimated $940K. The largest seller was StoneX Group, exiting entirely with an estimated $14.2K sold.

  • 22 institutional investors held AEON Biopharma (AEON) as of Q4 2025, up from 21 in Q3 2025.
  • Funds reported $1.67M of AEON Biopharma stock for Q4 2025, up 51% quarter-over-quarter.
  • 4 funds opened new AEON Biopharma positions in Q4 2025 and 3 closed out, a net change of +1 holder.
  • The largest AEON Biopharma buyer in Q4 2025 was Dauntless Investment Group, an estimated $940K added.
  • The largest AEON Biopharma seller in Q4 2025 was StoneX Group, an estimated $14.2K sold.

Based on aggregated 13F filings for Q4 2025.